NICE approves taxanes for breast cancerBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7251.1688/a (Published 24 June 2000) Cite this as: BMJ 2000;320:1688
- Caroline White
The National Institute for Clinical Excellence (NICE) last week approved the use of taxanes for the treatment of advanced breast cancer for women in England and Wales.
A course of treatment will cost around £1500 ($2250) and is expected to add £16m to the NHS annual drugs bill. Last month the Department of Health asked the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial